Alx Oncology Financials

ALXO Stock  USD 11.15  0.26  2.28%   
Based on the key measurements obtained from Alx Oncology's financial statements, Alx Oncology Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Alx Oncology's Cash And Short Term Investments are very stable compared to the past year. As of the 29th of March 2024, Liabilities And Stockholders Equity is likely to grow to about 254.7 M, while Other Liabilities is likely to drop about 57.9 K. Key indicators impacting Alx Oncology's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio4.985.2404
Notably Down
Pretty Stable
The financial analysis of Alx Oncology is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Alx Oncology includes many different criteria found on its balance sheet. For example, investors should never minimize Alx Oncology's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Alx Oncology's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Alx Oncology.

Net Income

(152.76 Million)

With this module, you can analyze Alx financials for your investing period. You should be able to track the changes in Alx Oncology individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Alx Oncology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Alx Oncology's financial statements are interrelated, with each one affecting the others. For example, an increase in Alx Oncology's assets may result in an increase in income on the income statement.
Evaluating Alx Oncology's financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Alx Oncology's profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Alx Oncology's relative financial performance

Chance Of Distress

Less than 23

 
100  
 
Zero
Low
Alx Oncology Holdings has less than 23 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Alx Oncology stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Alx Oncology's odds of distress score SHOULD NOT be confused with the real chance of Alx Oncology Holdings filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Alx is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Alx Oncology's liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Alx Oncology's official financial statements usually reflect Alx Oncology's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Alx Oncology Holdings. For example, before you start analyzing numbers published by Alx accountants, it's critical to develop an understanding of what Alx Oncology's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Alx Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alx Oncology's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Alx Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Alx Oncology Holdings. Please utilize our Beneish M Score to check the likelihood of Alx Oncology's management manipulating its earnings.

Alx Oncology Company Summary

Alx Oncology competes with Mustang Bio, Moleculin Biotech, Kineta, Mediwound, and YS Biopharma. ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company was founded in 2015 and is headquartered in South San Francisco, California. Alx Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS00166B1052
CUSIP00166B105
LocationCalifornia; U.S.A
Business Address323 Allerton Avenue,
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.alxoncology.com
Phone650 466 7125
CurrencyUSD - US Dollar
You should never invest in Alx Oncology without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Alx Stock, because this is throwing your money away. Analyzing the key information contained in Alx Oncology's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Alx Oncology Key Financial Ratios

Generally speaking, Alx Oncology's financial ratios allow both analysts and investors to convert raw data from Alx Oncology's financial statements into concise, actionable information that can be used to evaluate the performance of Alx Oncology over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Alx Oncology Holdings reports annually and quarterly.

Alx Oncology Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets10.7M436.1M380.2M306.5M242.6M254.3M
Other Current Liab1.2M6.2M257K19.2M25.8M27.1M
Other Liab547K5K1.8M53K61.0K57.9K
Net Tangible Assets(70.6M)429.8M363.0M263.5M303.0M205.5M
Net Debt(3.6M)(434.2M)(362.9M)(272.5M)(5.2M)(5.5M)
Retained Earnings(72.8M)(118.5M)(202.0M)(325.5M)(486.3M)(462.0M)
Accounts Payable3.7M4K3.8M8.1M8.6M4.6M
Cash9.0M434.2M363.7M282.9M22.4M21.3M
Capital Surpluse2.1M548.3M565.0M589.7M678.2M375.5M
Other Current Assets256K1.8M3.4M4.8M4.9M2.9M
Total Liab11.0M436.1M17.1M43.0M52.8M74.9M
Net Invested Capital(65.2M)429.8M363.0M272.9M199.4M210.5M
Total Current Assets9.8M434.2M367.0M271.0M188.7M234.8M
Net Working Capital4.8M429.8M351.7M242.6M152.7M218.2M

Alx Oncology Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Alx Oncology's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Net Interest Income(21K)(811K)(13K)4.3M9.1M9.5M
Interest Expense21K811K13K4.4M1.6M1.2M
Gross Profit436K107K(736K)(1.5M)(836K)(794.2K)
Operating Income(19.2M)(43.7M)(83.6M)(127.4M)(170.3M)(161.8M)
Ebit(19.2M)(43.7M)(83.6M)(127.4M)(170.3M)(161.8M)
Research Development16.3M29.0M60.2M98.4M141.8M148.9M
Ebitda(18.8M)(44.1M)(83.5M)(127.1M)(169.4M)(161.0M)
Cost Of Revenue4.4M1.1M736K1.5M836K1.4M
Income Before Tax(19.2M)(45.5M)(83.5M)(123.4M)(160.8M)(152.8M)
Net Income(19.2M)(45.7M)(83.5M)(123.5M)(160.8M)(152.8M)
Income Tax Expense34K241K(21K)64K57.6K58.1K

Alx Oncology Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Alx Oncology Holdings. It measures of how well Alx is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Alx Oncology brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Alx had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Alx Oncology has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Investments(353K)610K(4.9M)(234.0M)44.7M46.9M
Change In Cash755K425.2M(70.6M)(314.8M)(26.4M)(25.1M)
Free Cash Flow(14.6M)(38.3M)(73.0M)(90.7M)(131.6M)(125.1M)
Depreciation429K202K51K342K836K420.0K
Capital Expenditures353K31K4.9M1.4M1.3M1.6M
Net Income(19.2M)(45.7M)(83.5M)(123.5M)(160.8M)(152.8M)
End Period Cash Flow9.0M434.2M363.7M48.9M22.4M21.3M
Change To Netincome297K6.6M19.3M23.8M27.4M28.8M

Alx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Alx Oncology's current stock value. Our valuation model uses many indicators to compare Alx Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alx Oncology competition to find correlations between indicators driving Alx Oncology's intrinsic value. More Info.
Alx Oncology Holdings is rated fifth in return on asset category among related companies. It is number one stock in cash per share category among related companies . At this time, Alx Oncology's Cash Per Share is very stable compared to the past year.. Comparative valuation analysis is a catch-all model that can be used if you cannot value Alx Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Alx Oncology's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alx Oncology's earnings, one of the primary drivers of an investment's value.

Alx Oncology Holdings Systematic Risk

Alx Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Alx Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Alx Oncology Holdings correlated with the market. If Beta is less than 0 Alx Oncology generally moves in the opposite direction as compared to the market. If Alx Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Alx Oncology Holdings is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Alx Oncology is generally in the same direction as the market. If Beta > 1 Alx Oncology moves generally in the same direction as, but more than the movement of the benchmark.

About Alx Oncology Financials

What exactly are Alx Oncology Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Alx Oncology's income statement, its balance sheet, and the statement of cash flows. Potential Alx Oncology investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Alx Oncology investors may use each financial statement separately, they are all related. The changes in Alx Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alx Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Alx Oncology Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Alx Oncology is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Alx has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Alx Oncology's financials are consistent with your investment objective using the following steps:
  • Review Alx Oncology's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Alx Oncology's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Alx Oncology's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Alx Oncology's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Alx Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Alx Oncology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Alx Oncology growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.18)

At this time, Alx Oncology's Price Earnings To Growth Ratio is very stable compared to the past year.

Alx Oncology March 29, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Alx Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Alx Oncology Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Alx Oncology Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Alx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Alx Oncology's daily price indicators and compare them against related drivers.
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Alx Stock analysis

When running Alx Oncology's price analysis, check to measure Alx Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alx Oncology is operating at the current time. Most of Alx Oncology's value examination focuses on studying past and present price action to predict the probability of Alx Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alx Oncology's price. Additionally, you may evaluate how the addition of Alx Oncology to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Alx Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.74)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.39)
Return On Equity
(0.71)
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.